The possible sequelae of continuous enlargement of dentigerous cyst are expansion of the alveolar bone, displacement of teeth, severe root resorption of teeth, expansion of buccal and lingual cortex and pain. Potential complications are development of cellulitis, deep neck infection, ameloblastoma, epidermoid carcinoma or mucoepidermoid carcinoma. Investigations
Early detection and removal of the cysts is essential to reduce morbidity since dentigerous cyst can attain considerable size without any symptoms. Patient who presents with unerupted teeth should be thoroughly examined with radiographic examinations to check our for dentigerous cysts. Panoramic radiographs may be indicated for this purpose. CT imaging becomes necessary for extensive lesion. Pathologic analysis of the lesion is important for the definitive diagnosis even though radiographs provide valuable information. Histopathologic Features
The histopathologic features of dentigerous cyst are dependent on the nature of the cyst, whether it is inflamed or not inflamed. Non-inflamed dentigerous cystThe specimen will present with loosely arranged fibrous connective tissue wall that contains considerable glycosaminoglycan ground substance. Small islands or cords of inactive-appearing odontogenic epithelial rests are usually scattered within the connective tissue and most commonly located near the epithelial lining. These rests may appear numerous in the fibrous connective tissue wall occasionally, which may be misinterpreted as ameloblastoma by some pathologists who are unfamiliar with oral lesions. The epithelial lining is composed of two to four layers of flattened non-keratinizing cells, with a flat epithelium and connective tissue interface. Inflamed dentigerous cystOccurrence of inflamed dentigerous cyst is fairly common.
In July of that year AstraZeneca licensed tralokinumab to Leo Pharma for skin diseases.A phase IIb study of tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis.On 15 June 2017, Leo Pharma announced that they were starting phase III clinical trials with tralokinumab in atopic dermatitis. Society and culture
Legal status
On 22 April 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Adtralza, intended for the treatment of moderate‑to‑severe atopic dermatitis. The applicant for this medicinal product is LEO Pharma A/S. Tralokinumab was approved for medical use in the European Union in June 2021. Names
Tralokinumab is the international nonproprietary name (INN) and the United States Adopted Name (USAN). References
External links
"Tralokinumab". Drug Information Portal. U.S. National Library of Medicine.